middle.news
Imagion Restarts MagSense Manufacturing Ahead of Planned Cancer Trials
9:03am on Monday 14th of September, 2026 AEST
•
Biotechnology and healthcare
Read Story
Imagion Restarts MagSense Manufacturing Ahead of Planned Cancer Trials
9:03am on Monday 14th of September, 2026 AEST
Key Points
Master Service Agreement with nanoComposix
GMP-aligned pharmaceutical-grade nanoparticle production
Support for planned HER2 clinical studies
No disclosed contract value or production volumes
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imagion Biosystems (ASX:IBX)
OPEN ARTICLE